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Abstract
Background and Objectives We aimed to study the
impact of size, maturation and cytochrome P450 2D6
(CYP2D6) genotype activity score as predictors of intra-
venous tramadol disposition.
Methods Tramadol and O-desmethyl tramadol (M1)
observations in 295 human subjects (postmenstrual age
25 weeks to 84.8 years, weight 0.5–186 kg) were pooled. A
population pharmacokinetic analysis was performed using a
two-compartment model for tramadol and two additional M1
compartments. Covariate analysis included weight, age, sex,
disease characteristics (healthy subject or patient) and
CYP2D6 genotype activity. A sigmoid maturation model was
used to describe age-related changes in tramadol clearance
(CLPO), M1 formation clearance (CLPM) and M1 elimina-
tion clearance (CLMO). A phenotype-based mixture model
was used to identify CLPM polymorphism.
Results Differences in clearances were largely accounted
for by maturation and size. The time to reach 50 % of adult
clearance (TM50) values was used to describe maturation.
CLPM (TM50 39.8 weeks) and CLPO (TM50 39.1 weeks)
displayed fast maturation, while CLMO matured slower,
similar to glomerular filtration rate (TM50 47 weeks). The
phenotype-based mixture model identified a slow and a
faster metabolizer group. Slow metabolizers comprised
9.8 % of subjects with 19.4 % of faster metabolizer CLPM.
Low CYP2D6 genotype activity was associated with lower
(25 %) than faster metabolizer CLPM, but only 32 % of
those with low genotype activity were in the slow metab-
olizer group.
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Conclusions Maturation and size are key predictors of
variability. A two-group polymorphism was identified
based on phenotypic M1 formation clearance. Maturation
of tramadol elimination occurs early (50 % of adult value
at term gestation).
Key Points
Size and maturation are the principal predictors of
differences in the pharmacokinetics of tramadol and
its O-desmethyl tramadol (M1)
After accounting for size and maturation, the
phenotypic expression of metabolism of tramadol to
M1 is described by two groups with 9.8 % having
slow (5.4 % conversion to M1) and the rest having
faster formation clearance (33 % conversion to M1)
Maturation of tramadol elimination occurs early,
with 50 % of adult-size standardised clearance at
term gestation
1 Introduction
Tramadol is a racemic mixture of the two enantiomers,
(?)-tramadol hydrochloride and (-)-tramadol hydrochlo-
ride. It is a 4-phenyl piperidine analogue of codeine. The
analgesic effects of tramadol are mediated through nor-
adrenaline re-uptake inhibition, increased serotonin release
and decreased serotonin re-uptake in the spinal cord [1, 2].
Tramadol itself also has a weak l-opioid receptor effect
with a receptor affinity that is 6,000 times lower than
morphine. Tramadol is metabolized by O-demethylation
cytochrome P450 2D6 [CYP2D6] to O-desmethyl tramadol
(M1) or by N-demethylation (CYP3A) to N-desmethyl
tramadol (M2). The M2 metabolite appears to be inactive
[2, 3], but the O-desmethyl tramadol (?)-M1 metabolite
has a l-opioid receptor affinity approximately 200 times
higher than tramadol. Consequently, CYP2D6 polymor-
phisms influence (?)-M1 production with subsequent dif-
ferences in analgesia [1, 4].
Besides CYP2D6 polymorphisms, extensive between-
individual variability in tramadol disposition has been
linked to size, age, co-medication and co-morbidity [5–8].
Total tramadol clearance has been estimated for adults
(28 L/h), children aged 1–7 years (8.86 L/h/70 kg), and
full-term gestation neonates and infants (17.1 L/h/70 kg)
[1, 5]. M1 formation clearance was very low in preterm
neonates, irrespective of the CYP2D6 genotype activity
score. Subsequent maturation, i.e. the emergence of char-
acteristics through growth processes as reflected in age,
was described by an exponential function and was associ-
ated with CYP2D6 activity score but an upper plateau was
not yet observed in the 25–52 weeks postmenstrual age
range [6]. Others have reported an association between
CYP2D6 genotype and tramadol metabolism in both heal-
thy adult volunteers [7] and surgical adult patients [8].
Similar data on tramadol disposition in children were also
reported [9–11]. Because the fractional clearance of tram-
adol to M1 was not identifiable in these individual studies,
there is no quantitative estimate of the difference in M1
formation in subjects identified as slow metabolizers
whether by phenotypic or genotypic methods. However,
the expected presence of two subpopulations in children
was confirmed by a bimodal distribution of M1/tramadol
ratio of area under the plasma–concentration time curve in
a study of children 1–8 years of age. Weight was also a
major covariate of clearance in this study [11].
The current investigation describes the use of matura-
tion, size and CYP2D6 phenotype as predictors of intra-
venous tramadol disposition in premature neonates through
to adults, using a pooled population analysis approach [5–
7, 9–17].
2 Methods
2.1 Data
Time–concentration profiles from pharmacokinetic studies
on intravenous tramadol were pooled for this population
analysis [5–7, 9–17]. Data were only included if the pub-
lished manuscript stated that the study was approved by an
institutional review board. Consequently, no additional
ethical approval for the pooled analysis was requested.
Individual time–concentration profiles collected in infants
(age \2 years), children (age C2 years) and adults (age
[20 years) were provided by the authors of the initial
studies. CYP2D6 genotypes were available in 137/295
human subjects. CYP2D6 genotype activity was classified
as being low (active allele score 0 or 0.5) [20 subjects] or
normal (active allele score 1, 1.5, 2, or more) [117 subjects]
[8, 18, 19]. A summary of the analytical techniques for
tramadol and M1 and the clinical characteristics and
sampling strategy as applied in these studies, and the
studies codes are shown in Tables 1 and 2, respectively [5–
7, 9–17, 20–25]. Further details about the clinical charac-
teristics are available in supplementary Table S1.
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2.2 Pharmacokinetic Analysis
A two-compartment (central and peripheral), zero-order
input, first-order elimination model was used to describe
tramadol disposition. An additional two compartments
were used to represent the M1 metabolite (Fig. 1).
Alternative structural models with one and three distri-
bution compartments and mixed-order elimination of the
major pathways were examined and rejected on the basis
of goodness-of-fit criteria. An estimate of the volume of
distribution of the M1 metabolite is required to define
tramadol elimination clearance by transformation to M1
(CLPM). Pharmacokinetic studies in dogs were included
to estimate the volume of distribution of the M1 metab-
olite (VM1). These dog studies included intravenous
administration of tramadol [23, 24] and of particular
importance to this analysis, the M1 metabolite was
directly administered intravenously [23]. Further details
can be found in a cross-species pharmacokinetic analysis
of tramadol and M1 [26].
Parameter estimation was performed using NONMEM
version VII level 1.3 with the first-order conditional
interaction method. Standard errors of the estimates were
obtained by non-parametric bootstrapping [27]. Models
were compiled with Intel Visual Fortran version 11 and
executed on an Intel Xeon E5335 Processor with Windows
2003 Server Service Pack 2. Model building was based on
NONMEM’s objective function and by a visual predictive
check [28] with prediction correction [29]. Models were
nested and an improvement in the objective function was
referred to the v2 distribution to assess statistical signifi-
cance, e.g. an objective function change (DOBJ) of 3.84 is
significant at a = 0.05 with one additional parameter in the
model.
Reported tramadol hydrochloride doses were converted
to base tramadol, where 1 mg tramadol hydrochloride is
equal to 0.8784 mg of tramadol. M1 concentrations were
converted to tramadol milligram equivalents for a simul-
taneous parent and metabolite fit using a molecular weight
of 249.38 mg/mmol for M1 and 263.38 mg/mmol for
tramadol (molar ratio 0.947). Stereo-selective M1 con-
centration measurements were converted to racemic con-
centrations by summation of stereo-isomer concentrations.
M1 measurements from dog study code number 20 were
not used because of co-elution with other tramadol
metabolites [14]. All other assays are believed to be
selective for M1 [5–7, 9–13, 15–17, 23, 24].
Clearance and volume parameters were standardised
to a body weight of 70 kg using an allometric model [30]
(Eq. 1)
Fsize ¼ Wi
WSTD
 PWR
ð1Þ
T
a
b
le
1
S
u
m
m
ar
y
o
f
an
al
y
ti
ca
l
m
et
h
o
d
s
P
u
b
li
ca
ti
o
n
R
ef
er
en
ce
s
[5
,
6
]
R
ef
er
en
ce
[9
]
R
ef
er
en
ce
s
[1
2
–
1
6
]
R
ef
er
en
ce
[1
1
]
R
ef
er
en
ce
[7
]
R
ef
er
en
ce
[1
0
]
R
ef
er
en
ce
[1
7
]
R
ef
er
en
ce
[2
3
,
2
4
]
R
ef
er
en
ce
[2
3
,
2
4
]
S
tu
d
y
co
d
e
1
2
3
4
5
6
7
2
0
an
d
2
1
2
2
A
n
al
y
ti
ca
l
m
et
h
o
d
H
P
L
C
fl
u
o
re
sc
en
ce
d
et
ec
ti
o
n
G
as
ch
ro
m
at
o
g
ra
p
h
y
w
it
h
n
it
ro
g
en
-
se
le
ct
iv
e
d
et
ec
ti
o
n
[2
0
]
G
as
ch
ro
m
at
o
g
ra
p
h
y
w
it
h
n
it
ro
g
en
-
se
le
ct
iv
e
d
et
ec
ti
o
n
[2
0
]
L
C
-M
S
/M
S
H
P
L
C
fl
u
o
re
sc
en
ce
d
et
ec
ti
o
n
G
as
ch
ro
m
at
o
g
ra
p
h
y
w
it
h
n
it
ro
g
en
-
se
le
ct
iv
e
d
et
ec
ti
o
n
[2
0
]
L
C
-M
S
H
P
L
C
fl
u
o
re
sc
en
ce
d
et
ec
ti
o
n
[2
1
,
2
2
]
H
P
L
C
fl
u
o
re
sc
en
ce
d
et
ec
ti
o
n
[2
5
]
L
L
O
Q
0
.0
5
m
g
/L
(T
,
M
1
)
0
.0
0
2
;
0
.0
0
2
5
m
g
/L
(T
,
M
1
)
0
.0
0
1
3
m
g
/L
0
.0
0
0
5
m
g
/L
(T
,
M
1
)
1
n
m
o
l/
L
(T
,
M
1
)
0
.0
0
3
m
g
/L
(T
,
M
1
)
0
.0
0
3
m
g
/L
(T
)
C
V
%
\
2
0
5
5
5
6
\
8
.5
6
H
P
L
C
h
ig
h
-p
er
fo
rm
an
ce
li
q
u
id
ch
ro
m
at
o
g
ra
p
h
y
,
L
C
-M
S
li
q
u
id
ch
ro
m
at
o
g
ra
p
h
y
-m
as
s
sp
ec
tr
o
m
et
ry
,
L
C
-M
S
/M
S
li
q
u
id
ch
ro
m
at
o
g
ra
p
h
y
-t
an
d
em
m
as
s
sp
ec
tr
o
m
et
ry
,
T
tr
am
ad
o
l,
M
1
O
-d
es
m
-
et
h
y
l
tr
am
ad
o
l,
L
L
O
Q
lo
w
er
li
m
it
o
f
q
u
an
ti
fi
ca
ti
o
n
;
C
V
co
ef
fi
ci
en
t
o
f
v
ar
ia
ti
o
n
Tramadol Disposition Throughout Human Life
T
a
b
le
2
S
u
m
m
ar
y
o
f
cl
in
ic
al
ch
ar
ac
te
ri
st
ic
s
an
d
b
lo
o
d
sa
m
p
li
n
g
P
u
b
li
ca
ti
o
n
R
ef
er
en
ce
s
[5
,
6
]
R
ef
er
en
ce
[9
]
R
ef
er
en
ce
s
[1
2
–
1
6
]
R
ef
er
en
ce
[1
1
]
R
ef
er
en
ce
[7
]
R
ef
er
en
ce
[1
0
]
R
ef
er
en
ce
[1
7
]
R
ef
er
en
ce
[2
3
]
R
ef
er
en
ce
[2
3
]
R
ef
er
en
ce
[2
4
]
S
tu
d
y
co
d
e
1
2
3
4
5
6
7
2
0
2
1
2
2
C
li
n
ic
al
g
ro
u
p
N
eo
n
at
es
o
r
in
fa
n
ts
af
te
r
su
rg
er
y
o
r
m
ed
ic
al
co
n
d
it
io
n
s
C
h
il
d
re
n
af
te
r
su
rg
er
y
H
ea
lt
h
y
ad
u
lt
s
C
h
il
d
af
te
r
ab
d
o
m
in
al
la
p
ar
o
sc
o
p
ic
su
rg
er
y
H
ea
lt
h
y
ad
u
lt
s
C
h
il
d
re
n
af
te
r
ab
d
o
m
in
al
an
d
u
ro
lo
g
y
su
rg
er
y
A
d
u
lt
s
af
te
r
ab
d
o
m
in
al
su
rg
er
y
A
d
u
lt
d
o
g
s
A
d
u
lt
d
o
g
s
A
d
u
lt
d
o
g
A
v
er
ag
e
w
ei
g
h
t
k
g
(r
an
g
e)
3
.0
(0
.5
–
6
.1
)
1
3
.3
(8
.5
–
2
4
)
7
1
.1 (5
8
–
9
8
)
1
5
.8
(8
.9
–
3
3
)
7
7
.3
(6
5
–
8
7
)
1
9
.8
(1
0
–
4
3
)
7
7
(4
8
–
1
8
6
)
9
.4 (
7
.3
–
1
2
.4
)
1
0
.9 (9
.7
–
1
1
.9
)
2
0
.5 (1
8
–
2
3
)
A
v
er
ag
e
P
N
A
(r
an
g
e)
2
.6
w
ee
k
s
(0
.1
–
2
1
.3
)
1
3
7
.8
w
ee
k
s
(6
1
–
3
4
2
)
3
6
.5
y
ea
rs
(2
1
.1
–
6
0
)
1
6
8
w
ee
k
s
(6
1
–
4
2
5
)
2
5
y
ea
rs
(2
2
–
3
1
)
2
4
5
w
ee
k
s
(1
0
4
–
4
1
6
)
6
0
y
ea
rs
(2
6
–
8
4
)
A
v
er
ag
e
P
M
A
(r
an
g
e)
3
9
.1
w
ee
k
s
(2
5
–
5
4
)
1
7
3
.3
w
ee
k
s
(1
0
1
–
3
8
2
)
3
7
.3
y
ea
rs
(2
2
.1
–
6
1
)
2
1
7
.2
w
ee
k
s
(1
0
1
–
4
6
5
)
2
5
.8
y
ea
rs
(2
2
.8
–
3
1
.8
)
2
8
5
w
ee
k
s
(1
4
4
–
4
5
6
)
6
0
.8
y
ea
rs
(2
6
.8
–
8
4
.8
)
D
ev
ia
ti
o
n
s
fr
o
m
p
u
b
li
sh
ed
n
u
m
b
er
s
M
is
si
n
g
1
su
b
je
ct
5
su
b
je
ct
s
n
o
t
u
se
d
b
ec
au
se
d
o
se
w
as
n
o
t
IV
1
su
b
je
ct
re
m
o
v
ed
b
ec
au
se
o
f
d
o
se
ir
re
g
u
la
ri
ty
N
o
n
e
M
is
si
n
g
1
2
su
b
je
ct
s
O
n
ly
5
7
su
b
je
ct
s
u
se
d
,
o
th
er
s
h
ad
ad
d
it
io
n
al
b
o
lu
se
s
N
u
m
b
er
o
f
su
b
je
ct
s
5
6
9
4
1
2
4
1
6
9
3
5
6
6
3
6
L
o
ad
in
g
d
o
se
o
f
tr
am
ad
o
l
H
C
L
ex
ce
p
t
M
1
(b
as
e)
fo
r
st
u
d
y
2
1
2
–
3
m
g
/k
g
o
v
er
3
0
m
in
2
m
g
/k
g
o
v
er
3
0
m
in
1
0
0
m
g
b
o
lu
s
th
en
,
5
0
m
g
o
v
er
3
0
m
in
2
m
g
/k
g
o
v
er
1
0
m
in
1
0
0
m
g
b
o
lu
s
1
m
g
/k
g
o
v
er
2
.5
m
in
,
th
en
as
re
q
u
ir
ed
0
.3
3
m
g
/
k
g
at
1
5
,
3
0
,
4
5
m
in
3
m
g
/k
g
o
v
er
1
8
m
in
4
.4
m
g
/k
g
1
m
g
/k
g
(M
1
)
4
m
g
/k
g
M
ai
n
te
n
an
ce
in
fu
si
o
n
5
–
8
m
g
/k
g
o
v
er
2
4
h
N
o
n
e
N
o
n
e
8
m
g
/k
g
o
v
er
2
4
h
N
o
n
e
N
o
n
e
N
o
n
e
N
o
n
e
N
o
n
e
N
o
n
e
D
u
ra
ti
o
n
o
f
sa
m
p
li
n
g
(h
)
2
4
2
0
2
4
–
3
0
.5
3
6
4
8
6
3
6
4
2
4
N
o
m
in
al
o
b
se
rv
at
io
n
s/
su
b
je
ct
1
0
1
4
1
0
1
0
1
3
3
3
1
2
9
1
2
A
v
er
ag
e
o
b
se
rv
at
io
n
s/
su
b
je
ct
(t
ra
m
ad
o
l)
5
1
3
1
5
9
1
3
2
3
8
–
9
A
v
er
ag
e
o
b
se
rv
at
io
n
s/
su
b
je
ct
(M
1
)
4
1
2
0
9
1
3
2
3
8
8
6
IV
in
tr
av
en
o
u
s,
P
N
A
p
o
st
n
at
al
ag
e,
P
M
A
p
o
st
m
en
st
ru
al
ag
e,
M
1
O
-d
es
m
et
h
y
l
tr
am
ad
o
l
K. Allegaert et al.
where Wi is the weight in the ith individual. Allometric
scaling with a PWR exponent of 3/4 for clearance and 1 for
volume of distribution was employed because of its strong
theoretical and empirical basis [31]. Fsize is the allometri-
cally scaled fraction of the parameter value in a subject
with a standard weight of 70 kg, WSTD.
Covariate analysis included a sigmoid maturation model
to describe age-related changes for parent tramadol clear-
ance (CLPO), M1 formation clearance (CLPM) and M1
elimination clearance (CLMO) (Eq. 2) [32–34]. The
pharmacokinetic model for tramadol and M1 is illustrated
in Fig. 1.
Fmat ¼ 1
1  PMATM50
 ðHillÞ ð2Þ
where Fmat is the maturation fraction relative to a mature
adult; PMA is the postmenstrual age in weeks, TM50 is the
PMA at which clearance is 50 % of the mature value; and
Hill is the Hill coefficient that modifies the steepness of the
maturation curve. Disease status (healthy subject/volunteer
or patient receiving pain treatment), sex (male, female) and
CYP2D6 activity were used to estimate fractional differ-
ences in model parameters. Fractional differences in
structural parameters were tested for all subject types (e.g.
dog, infant, child) relative to adults. These fixed effects
were retained in the model if the 95 % bootstrap confi-
dence interval for the parameter estimate did not include 1.
Covariance between random effects was accepted if the
95 % bootstrap confidence interval for correlation between
two random effects did not include 0.
A mixture model was used to distinguish slow from
faster metabolizers of tramadol on the basis of their phe-
notype. This method estimates the fraction of all subjects
(humans and dogs) who appear to be in a slow metabolizer
subgroup and the fraction of CLPM relative to CLPM in
faster metabolizers. A three-group mixture model was
investigated after development of the final two-mixture
group model to see if it was possible to identify poor,
intermediate and extensive metabolizer groups. A geno-
type-based model used the 20 subjects with a low CYP2D6
genotype activity (active allele score \1). The fractional
difference in M1 formation clearance was estimated in this
group compared with the rest of the subjects, including
both the cases with higher (n = 117, CYP2D6 genotype
activity active allele score C1) and unknown (n = 158)
CYP2D6 genotype.
Study code 2 has been previously reported with lower
total tramadol clearance in children (0.36 L/h/kg) [9],
which was approximately half that described by others
(0.8 L/h/kg) despite similar age and weight ranges in all
three studies (1–8 years) [10, 11]. Quantification of
clearance reduction for study code 2 [9] was undertaken by
investigating scaling parameters (Fstudy) for that study to
tramadol and M1 pharmacokinetic parameters. Central
volume of distribution of tramadol (VP1) in neonates
(postnatal age \21 days) has been reported to be greater
than that observed in older children and adults [5]. A scale
parameter was used to look for this difference and other
study specific differences in PK parameters using an
expression such as that shown in Eq. (3).
if (study ¼ 2Þ then
FsdyCL ¼ Fstudy2CL
else
FsdyCL ¼ 1
endif
Group parameters were based on fixed effects on
pharmacokinetic parameters, e.g. for clearance (Eq. 4)
using maturation (Fmat), size (Fsize) and study code (Fstudy).
CLGRP ¼ CLSTD  Fmat  Fsize  Fstudy ð4Þ
Individual parameter estimates were predicted from the
group estimate and the variance of gi, the random between-
subject differences in the parameter, using an exponential
model (Eq. 5).
CLi ¼ CLGRP  expðgiÞ ð5Þ
Fig. 1 Pharmacokinetic model for tramadol and M1. A two-com-
partment linear-disposition model describes the parent drug with
inter-compartmental clearance CLICP. Total clearance of tramadol is
the sum of CLPM and CLPO. An additional two compartments for the
metabolite M1 are linked to the tramadol central compartment by M1
formation clearance. CLICM is the inter-compartmental clearance of
M1. CLMO clearance of M1, M1 O-desmethyl tramadol, CLICp inter-
compartmental clearance, CLPM tramadol clearance to M1, CLPO
tramadol clearance by other routes, CLMO clearance of M1, VP1,
VP2, VM1 and VM2 are respectively the central and peripheral
distribution volume of either tramadol (P) or O-desmethyl tramadol
(M)
Tramadol Disposition Throughout Human Life
Residual unidentified variability was described using a
combined proportional and additive residual error model
for each observation prediction with random differences,
ePROP, eADD, The between-subject variability (gRUV,i) in the
residual unidentified variability was estimated [35].
Between-subject differences in residual error were
separately identified for tramadol and M1. This is
illustrated for a concentration observation prediction
(Eq. 6).
Y ¼ C  ð1 þ ePROPÞ þ eADDð Þ  expðgRUV;iÞ ð6Þ
3 Results
The initial analysis fixed the current model parameters to
the human adult estimates obtained from the analysis of
tramadol and M1 data from adult humans and non-human
species [26]. This initial analysis was subsequently used to
learn about maturation of tramadol and M1 clearance in
human children under the assumption that mature adult
parameter values were known. Subsequently the adult
human parameters were re-estimated, using the combined
human adult and child datasets described above, which
allows the data from children to add further information
about the mature adult parameters under the assumptions of
the maturation model for clearances. The objective func-
tion dropped from 23,001 to 22,929 when the adult
parameters were allowed to change. Inclusion of the data
from human children was associated with changes in the
adult parameters relative to those estimated without the
paediatric data. These changes were a 13 % decrease in
CLPM, 5 % decrease in CLPM in phenotypically slow
metabolizers (CLPMslow), 23 % increase in CLPO, 13 %
increase in VP1, 85 % increase in the intercompartmental
clearance of M1, CLICM, and a 45 % increase in VM2.
Compared with a model with no covariates, the objec-
tive function improved by 1910 when size and maturation
was included, and by 1537 when just size was used.
CYP2D6 metabolism has been described in terms of
poor, intermediate and extensive metabolizer categories. A
three-group mixture model did not significantly improve
the fit (P [ 0.05) compared with a two-group mixture
model. Only 34 % of bootstrap data models favored the
three-group model based on objective function differences.
Only 9.3 % of subjects were classified as intermediate
metabolizers with 32.4 % poor metabolizers and 58 %
extensive metabolizers (supplementary material Table S2).
Removing the two-group mixture model for the distri-
bution of CLPM worsened the objective function highly
significantly (P = 2E - 10). This change for the removal of
three parameters provides strong support for the existence of
a subgroup of slow metabolizers relative to the rest of the
population.
The TM50 for CLMO was later than that estimated for
CLPM and CLPO. Because M1 or its glucuronide are most
likely eliminated by the renal route, the model was sim-
plified by assuming that the maturation of CLMO was the
same as that for the glomerular filtration rate (GFR)
(TM50 = 47.7 weeks, Hill = 3.4) [36]. The objective
function worsened by only one unit, which is not a sig-
nificant change with the removal of two estimated
parameters.
Parameter estimates are shown in Tables 3, 4, 5 and 6.
Scatterplots of individual predicted total tramadol clear-
ance (CLPM ? CLPO) and M1 formation clearance
(CLPM) are shown in Figs. 2 and 3, respectively. Com-
parison of adult human pharmacokinetic parameters with
dogs, neonates and children are provided in Table 7, while
clearance maturation parameters are shown in Table 8 and
displayed graphically in Fig. 4.
Figures 2 and 3 show that total tramadol clearance
(CLPM ? CLPO = CLP total), but not CLPM (clearance
to M1) appear to be lower in study code 2 [9]. A model that
estimated clearances in study code 2 relative to other
studies showed CLPO was 34.6 % (relative standard error
(RSE) 20 %) and CLMO was 52.7 % (RSE 14 %) of the
clearance relative to other studies. This model improved
the fit with a decrease in objective function of 64. In
contrast, there was no significant improvement in the
objective function when CLPM was allowed to be different
in Study code 2 (Table 7). The visual predictive check
plots for tramadol and M1 show good agreement between
the predicted and observed median and 90 % intervals
(supplementary material Figs. S1 and S2). This indicates
that the pharmacokinetic model and the statistical vari-
ability model are adequate to describe tramadol disposi-
tion. There was no discernible difference in total tramadol
clearance between males and females, or between patients
and healthy subjects.
The mixture model for identification of M1 metabolizer
type estimated that 9.8 % (RSE 33 %) of the human pop-
ulation were slow metabolizers and that these individuals
have 19.4 % (RSE 21 %) of the CLPM of faster metabo-
lizers. The fraction of tramadol converted to M1 was 0.33
(RSE 12 %) in the faster metabolizer group and 0.054
(RSE 2.1 %) in the slow metabolizer group. There were no
slow metabolizers identified in the dog studies although
relative to humans the size standardised CLPM in all the
dogs was low.
An exploratory analysis was conducted based on the
two-group mixture model with the selected subset of sub-
jects with a genotype activity group (low or normal).
Subjects without a genotype activity score were described
by phenotype using the two-group mixture model. The
fractional difference in CLPM in the low genotype activity
group was 0.236 (bootstrap 0.252, 95 % CI 0.130–0.461).
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Table 3 Original data and bootstrap parameter estimates with slow and faster metabolizer groups
Parameter Description Original Bootstrap
average
RSEa
(%)
2.5
percentile
97.5
percentile
Fslow Fraction slow metabolizers 0.0854 0.0983 33 0.0469 0.1624
CLPM L/h/70 kg Clearance of tramadol to M1 in faster
metabolizers
10.5 10.7 13 8.0 13.1
CLPM slow L/h/70 kg CLPM in phenotypically
slow metabolizers
1.83 2.07 25 1.25 3.31
CLPO L/h/70 kg Clearance of tramadol by other pathways 21.6 21.6 7 18.5 24.4
CLICP L/h/70 kg Inter-compartmental clearance of tramadol 227 230 12 181 292
VP1 L/70 kg Central volume of tramadol 51.0 49.4 16 35.4 62.4
VP2 L/70 kg Peripheral volume of tramadol 134 135 4 125 144
CLMO L/h/70 kg Clearance of M1 71.4 72.5 12 53.1 88.6
CLICM L/h/70 kg Inter-compartmental clearance of M1 562 635 52 349 1464
VM1 L/70 kg Central volume of M11 78.9 Fixedb
VM2 L/70 kg Peripheral volume of M1 133 136 15 91.3 175
a RSE, relative standard error = bootstrap (standard error/average) 9 100
b Fixed to value estimated in dogs administered M1 intravenously
Table 4 Original data and bootstrap population parameter variability estimates
PPV Original Bootstrap average RSE (%) 2.5 percentile 97.5 percentile
CLPM 0.322 0.303 17 0.184 0.396
CLPMslow 0.0460 0.0907 162 0.000 0.533
CLPO 0.754 0.749 14 0.534 0.978
CLICP 0.37 0.35 17 0.236 0.47
VP1 0.545 0.534 12 0.422 0.659
VP2 1.044 1.020 14 0.775 1.329
CLMO 0.445 0.435 14 0.313 0.551
CLICM 1.92 1.98 20 1.298 2.78
VM1 1.47 1.45 13 1.11 1.85
VM2 0.345 0.339 30 0.007 0.542
RUV CP 0.206 0.210 18 0.132 0.274
RUV CM 0.246 0.241 17 0.169 0.319
PPV population parameter variability [sqrt(NONMEM OMEGA estimate), CLPM clearance of tramadol to O-desmethyl tramadol, CLPO
clearance of tramadol by other pathways, VP1 central volume of tramadol, CLICP intercompartmental clearance of tramadol, CLICM inter-
compartmental clearance of O-desmethyl tramadol, VP2 peripheral volume of tramadol, VM1 central volume of O-desmethyl tramadol, VM2
peripheral volume of O-desmethyl tramadol, RUV residual unidentified variability
Table 5 Correlation of population parameter variability
Correlation Original Bootstrap average RSE (%) 2.5 percentile 97.5 percentile
R CLPM-VP1 -0.391 -0.373 39 -0.612 -0.052
R VP1-CLPO 0.772 0.761 9 0.613 0.887
R CLPO-VP2 0.390 0.396 24 0.219 0.587
R VP2-QP 0.639 0.633 17 0.411 0.810
R CLMO-VM1 0.865 0.865 8 0.678 0.996
CLPM clearance of tramadol to O-desmethyl tramadol, CLPO clearance of tramadol by other pathways, VP1 central volume of tramadol, VP2
peripheral volume of tramadol, VM1 central volume of O-desmethyl tramadol, VM2 peripheral volume of O-desmethyl tramadol
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The fractional difference in CLPM in the normal genotype
activity group was not significantly different from that in
the mixture-model faster metabolizer group.
Figure 5 shows that not all subjects with the low
CYP2D6 genotype activity were in the phenotypically
(CLPM) slow metabolizer group. While those subjects with
a low CYP2D6 genotype activity had reduced CLPM
compared with faster metabolizers, only 8 (42 %) out of 19
with the low CYP2D6 genotype activity were identified
phenotypically as slow metabolizers. In the cohort of 56
neonates and young infants (PMA B54 weeks), only 4
(7 %) were identified with low CYP2D6 genotype activity,
although none of these 4 neonates were identified as phe-
notypically slow metabolizers.
Because of the wide range of sizes (0.53–186 kg) in the
human studies, we attempted to estimate the allometric
exponent in the size model compared with theory-based
values. The objective function dropped by 6 units with an
estimate of 0.702 for the clearance size exponent. The
objective function dropped by 0.9 units with an estimate of
0.996 for the volume size exponent.
Covariance between five random-effects parameters was
identified in the final model. The residual unidentified
variability for both tramadol and M1 had proportional and
additive components. The fit was improved by adding a
between-subject variability random effect to the residual
unidentified variability.
4 Discussion
This pooled analysis provides evidence that differences in
tramadol and M1 pharmacokinetics between adults and
children (age range, 25 weeks PMA until 84.8 years;
weight range, 0.5–186 kg) can be largely accounted for by
differences in age and weight.
Maturation of the formation clearance of M1 occurs
early: 50 % of adult values are reached at a PMA of
39.8 weeks (TM50), i.e. shortly before full-term gestation
equivalent. A corresponding Hill coefficient of 9.39
implies very rapid maturation of CLPM around 40 weeks
PMA. CLPO maturation also occurs early (TM50
39.1 weeks) and changes rapidly with a Hill coefficient of
6.8.
In contrast, metabolite elimination clearance (CLMO)
matures more slowly and is compatible with GFR matu-
ration [36, 37]. Maturation of GFR function reaches 50 %
of adult values at 47.7 weeks PMA [36]. Clearance of
paracetamol and morphine (marker for glucuronidation
activity) mature shortly afterwards [38]. Thus, the matu-
ration of CYP2D6 activity occurs much sooner than the
Table 6 Residual unidentified variability (RUV) of tramadol and O-desmethyl tramadol (M1) concentration measurements
Parameter Description Original Bootstrap average RSE (%) 2.5 percentile 97.5 percentile
CV tramadol Proportional RUV tramadol 0.117 0.117 5 0.107 0.127
SD tramadol mcg/L Additive RUV tramadol 0.745 0.682 44 0.092 1.290
CV M1 Proportional RUV M1 0.155 0.153 8 0.131 0.173
SD M1 mcg/L Additive RUV M1 1.25 1.30 30 0.636 2.25
Fig. 2 Scatterplot of individual-predicted total tramadol
(CLPM ? CLPO) clearance vs. weight. The solid line reflects the
allometric model prediction for adult humans. Numbers for each
symbol refer to the study code, provided in Tables 1 and 2 [5–7, 9–17,
23, 24]. CLPM tramadol clearance to M1, CLPO tramadol clearance
by other routes
Fig. 3 Scatterplot of individual predicted clearance of tramadol to
M1 (CLPM) vs. weight. The solid line reflects the allometric model
prediction for adult humans. Numbers for each symbol refer to the
study code, provided in Tables 1 and 2 [5–7, 9–17, 23, 24]. M1
O-desmethyl tramadol, CLPM tramadol clearance to M1
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maturation of GFR or glucuronidation. We found that the
maturation of M1 elimination (CLMO) was indistinguish-
able from the maturation of GFR, which suggests that M1
elimination is likely to be by the renal route [37]. We found
that children in study code 2 had smaller CLPO and CLMO
but similar CLPM. We have no explanation for this finding,
but hereby confirm the lower than expected tramadol
clearance estimates reported in the original paper [9].
The value of the allometric exponent used to scale dif-
ferences in size was investigated. There was a statistically
significant but relatively small difference between the
theoretical value of  and the estimate of 0.702 for the
allometric exponent for clearance (Figs. 2, 3). This small
difference between the theoretical value and the estimated
value can be explained by empirical assumptions
associated with the sigmoidal maturation function whose
predictions may not be in fact completely independent of
size. We found no significant change and a negligible
difference between the theoretical value of 1 and the esti-
mated value of 0.999 for the volume allometric exponent.
The use of consistent allometric exponents for describing
differences in size is important for comparison across and
within species. Therefore, we claim that the current find-
ings support the use of an exponent of  for clearance and
1 for volume.
There was no plausible evidence for the existence of
separate poor, intermediate and extensive metabolizer
groups based on phenotype. We have therefore chosen to
use the term slow and faster to describe the two identifiable
metabolizer groups.
Table 7 Comparison of adult human pharmacokinetic parameters
with dogs, infants and children. Fractional differences relative to adult
human = 1. All other pharmacokinetic parameters had estimates
indistinguishable from the adult human value and the fraction was
fixed to 1 in the final model
Parameter Description Original Bootstrap average RSE (%) 2.5 percentile 97.5 percentile
CLPM ? CLPO Dog Study 20 6.16 6.21 13 5.12 8.16
CLPM Dog Study 22 0.113 0.118 27 0.089 0.155
CLPO Child Study 2 0.337 0.346 20 0.211 0.458
CLICP Dog Study 20,21 0.118 0.147 97 0.042 0.617
CLICP Child Study 2 0.172 0.166 43 0.047 0.346
CLICP Child Study 4 6.95 8.54 51 3.58 17.8
VP1 Dog Study 20,21 3.76 3.88 18 2.83 5.41
VP1 Child Study 2 1.84 2.03 23 1.26 2.97
VP1 Child Study 6 0.318 0.335 37 0.151 0.635
VP2 Dog Study 22 0.220 0.241 59 0.128 0.455
VP2 Infant Study 1 1.20 1.21 10 0.960 1.410
VP2 Child Study 2 0.547 0.541 22 0.341 0.789
CLMO Child Study 2 0.516 0.527 14 0.415 0.669
CLICM Infant Study 1 0.67 0.67 0 0.67 0.67
CLICM Child Study 2 0.169 0.261 103 0.08 0.997
CLICM Child Study 4 17.0 18.5 48 3.21 29.9
CLPM clearance of tramadol to O-desmethyl tramadol, CLPO clearance of O-desmethyl tramadol, CLICP intercompartmental clearance of
tramadol, VP1 central volume of tramadol, VP2 peripheral volume of tramadol, CLMO clearance of tramadol by other routes, CLICM inter-
compartmental clearance of O-desmethyl tramadol
Table 8 Maturation of clearance pathways for tramadol and O-desmethyl tramadol (M1)
Parameter Description Original Bootstrap average RSE (%) 2.5 percentile 97.5 percentile
TM50 CLPO weeks Maturation half-time CLPO 39.0 39.1 4 37.0 42.5
HILL CLPO Maturation Hill CLPO 6.76 6.81 33 3.61 11.4
TM50 CLPM weeks Maturation half-time CLPM 39.9 39.8 2 37.6 41.4
HILL CLPM Maturation Hill CLPM 9.00 9.39 18 6.97 13.9
TM50 CLMO weeks Maturation half-time CLMO 47.7
a Fixed
HILL CLMO Maturation Hill CLMO 3.4a Fixed
CLPO clearance of O-desmethyl tramadol, CLPM clearance of tramadol to O-desmethyl tramadol
a Fixed to same values estimated for glomerular filtration rate [36]
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We assumed that the CLPM clearance reflects pheno-
typic CYP2D6 activity because M1 is thought to be formed
by CYP2D6. The fraction of slow metabolizers in this
pooled analysis (9.8 %), as identified by the mixture
model, is similar to that reported for CYP2D6 genotypes
associated with poor CYP2D6 metabolism [39–41]. Fig-
ure 6 shows a histogram and model predictions of the
distribution of empirical Bayes estimates of CLPM after
standardising for fixed effects of size, maturation, and
Study 2 in humans using the final model. The existence of
two phenotypic groups is clearly visible.
The ability to identify the size of CLPM allowed us to
estimate that slow metabolizers have only 19.4 % of the
value in faster metabolizers. The combination of size,
maturation and a two-group mixture model accounted for
90 % of CLPM and 96 % of CLPO variance. These
covariates did not account for any of the variability of
CLPMslow because CLPMslow was estimated relative to
CLPM after fixed effects on CLPM had been accounted
for.
We found that CLPM in subjects with a low CYP2D6
genotype activity was 25 % of the phenotypic faster
metabolizer group value. In addition to size and age, we
anticipated that individual CYP2D6 genotypes would be
associated with differences in CLPM, but we found only
weak evidence for the additional relevance of the
CYP2D6 genotype activity method as a predictor of M1
formation. In Fig. 5, we show that only 8 out of 19
phenotypic slow metabolizers (42 %) had low CYP2D6
genotype activity, while in the normal metabolizer group
(n = 117), there were 11 (9 %) classified as phenotypic
slow metabolizers. This shows that CYP2D6 genotype
activity when used as a dichotomous variable is only one
of the determinants of CLPM. Obviously, the CYP2D6
genotype activity is much more complex with additional
variability both within the low genotype active allele
score \1 (either 0 or 0.5) and other genotype active
allele scores C1 (1, 1.5, 2 or [2). As mentioned earlier,
the (?)-enantiomer is a substrate of CYP2D6, while this
pooled dataset has been analysed using racemic plasma
concentrations. Moreover, polymorphism-related effects
may not be limited to drug metabolism, because organic
Fig. 4 Maturation of clearance. Clearance estimates for the M1
formation clearance, clearance by other routes and metabolite
clearance are expressed as a percentage of the mature value. M1 O-
desmethyl tramadol, CLPM tramadol clearance to M1, CLPO
tramadol clearance by other routes, CLMO clearance of M1, GFR
glomerular filtration rate
Fig. 5 Tramadol formation
clearance to O-desmethyl
tramadol, corrected for size,
plotted for each individual
Bayesian estimate, irrespective
of the availability of an
individual CYP2D6 genotype
activity score. There is a distinct
group of patients who are slow
metabolizers identified by the
phenotype-based mixture model
(dashed line). Not all subjects
with a low genotype CYP2D6
activity (n = 20) are included in
this slow metabolizer group [5–
7, 9–17]
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cation transporter 1 (OCT 1) polymorphisms may also
affect tramadol and M1 disposition [42]. Furthermore,
disease characteristics and co-medication also contribute
to the between-individual phenotypic CLPM. Study code
7 (see Table 2) included patients receiving other medi-
cations, including antidepressants, metoclopramide,
ranitidine or other medications known to affect enzyme
activity [17].
5 Conclusions
Tramadol and M1 disposition can be described using
models for maturation and size that have been reported
previously. The phenotypic expression of M1 formation
clearance is described by two groups of slow and faster
metabolizers. While the maturation of M1 elimination is
similar to GFR maturation, the maturation of tramadol
clearance occurs quite early with 50 % of the adult mature
value at the time of normal full-term gestation.
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